Neuronetics, Inc. announced that a peer-reviewed paper showed significantly lower seizure risk with NeuroStar® Advanced Therapy for Mental Health than with TMS treatments that claim deeper stimulation with H-Coil technology. The paper, titled “Seizure risk with repetitive TMS: Survey results from over a half-million treatment sessions” published in Brain Stimulation, the premier journal for publication of original research in the field of neuromodulation, electronically surveyed all of the approximately 500 members of the Clinical TMS Society (CTMSS) about seizures in their practice. One-hundred thirty-four surveys were returned and nine were excluded due to data inconsistencies, leaving a total of 125 surveys to evaluate which included 586,656 TMS treatment sessions. To distinguish seizures from non-seizures, a Board-certified neurologist and the Co-Chair of the CTMSS Standards Committee conducted remote interviews. The survey respondents included a wide range of clinical practices, and provided a way to estimate TMS seizure risk under real-world practice conditions. The resulting data provide the largest real-world sample size estimation of TMS seizure risk across device manufacturers. The authors hypothesized that the higher risk of seizure with the H-Coil design was due, in part, to the broader and less focused stimulation field which may stimulate unintended regions of the brain and lead to seizures.